Quantitative Systematic Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Quantitative Systematic Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,567	Closed	-$313K	–	676
2020 Q2	$313K	Buy	+2,567	New	+$284K	0.06%	403
2019 Q4	–	Sell	-4,699	Closed	-$423K	–	611
2019 Q3	$423K	Buy	4,699 +2,057	+78%	+$192K	0.1%	263
2019 Q2	$223K	Buy	+2,642	New	+$217K	0.04%	392
2017 Q4	–	Sell	-4,983	Closed	-$305K	–	620
2017 Q3	$305K	Buy	+4,983	New	+$263K	0.08%	331
2017 Q2	–	Sell	-6,017	Closed	-$261K	–	490
2017 Q1	$261K	Buy	+6,017	New	+$258K	0.07%	283
2016 Q3	–	Sell	-7,077	Closed	-$321K	–	450
2016 Q2	$321K	Buy	+7,077	New	+$326K	0.15%	205
2016 Q1	–	Sell	-5,641	Closed	-$319K	–	639
2015 Q4	$319K	Buy	+5,641	New	+$287K	0.09%	317

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Quantitative Systematic Strategies's NBIX Position: Q3 2020 in Review

Quantitative Systematic Strategies sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 2,567 shares — an estimated $313K sold.

Quantitative Systematic Strategies first reported a position in NBIX in Q4 2015 and held it in 7 quarters. The position peaked at $423K in Q3 2019. 419 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

Quantitative Systematic Strategies reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
Quantitative Systematic Strategies sold 2,567 Neurocrine Biosciences shares in Q3 2020, an estimated $313K.
Quantitative Systematic Strategies first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 7 quarters.
Quantitative Systematic Strategies's Neurocrine Biosciences position peaked at $423K in Q3 2019.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2020, filed 9 Nov 2020.